[1]. Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science, 2020; 368: 1012–1015. doi: 10.1126/science.abb7314.
[2]. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17: 181–192. doi: 10.1038/s41579-018-0118-9.
[3]. Chakraborty AK. Hyper-variable Spike protein of Omicron corona virus and its differences with Alpha and Delta variants: Prospects of RT-PCR and new vaccine. J Emerg Dis Virol. 2022; 7 (1):1-13. dx.doi.org/10.16966/2473-1846.166.
[4]. Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines.J Med Virol. 2022 May;94(5):1825-1832. doi: 10.1002/jmv.27588.
[5]. Ota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 2003; 300: 1394–1399. doi: 10.1126/science.1085952.
[6]. Chakraborty AK, Chanda A. New Biotechnological Exploration on COVID-19 Proteins: Functions, Mutational Profiles and Molecular Targets for Drug Design. Sun Text Rev Virol.2021; 2(1):115. Doi:10.51737/2766-5003.2021.015.
[7] Chakraborty AK. Coronavirus Nsp2 Protein Homologies to the bacterial DNA Topoisomerase I and IV Suggest Nsp2 Protein is a unique RNA Topoisomerase with novel target for drug and vaccine development. Virol Mycol. 2020; 9: 185. DOI: 10.35248/2161-0517.20.09.185.
[8]. Nguven TT, Pathirana PN, Abdelrazek M. Genomic mutations and changes in protein secondary structure and solvent accessibility of SARS-CoV-2. Scientific Reports, 2021; 11(3487). Doi: https://doi.org/10.1038/s41598-021-83105-3.
[9]. Noske GD, Nakamura AM, Gawriljuk VO, Fernandes RS, et al. A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process. J Mol Biol. 2021; 433: 167118.
[10]. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science, 2020; 368: 779-782.
[11]. Slanina H, Madhugiri R, Bylapudi G, et al. Coronavirus replication–transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit. Proc Natl Acad Sci. USA, 2021; 118(6): e2022310118. doi: 10.1073/pnas.2022310118.
[12]. Chakraborty AK. Multi-Alignment comparison of Coronavirus non-structural proteins Nsp13-16 with ribosomal proteins and other DNA/RNA modifying enzymes suggested their roles in the regulation of host protein synthesis. International J Clini Med Informatics, 2020; 3: 7-19. https://doi.org/10.46619/ijcmi.2020.1024.
[13]. Chakraborty AK. Clinical, Diagnostic and Therapeutic implications of Coronavirus ORFab Polyprotein associated Nsp16 Protein-A bioinformatics approach. Acta Scientific Medical Sciences, 2020; 4(5): 97-103. DOI: 10.31080/ASMS.2020.04.0629.
[14]. Addetia A, Xie H, Roychoudhury P, Shrestha L, Loprieno M, et al. Identification of multiple large deletions in ORF7a resulting in in-frame gene fusions in clinical SARSCoV-2 isolates. J Clin Virol. 2020; 129: 104523. https://doi. org/10.1016/j.jcv.2020.104523. PMID:
[15]. Al-Rashedi NAM, Alburkat H, Hadi AO, et al. High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in Iraq, winter 2020–2021. PLoS One, 2022; 17(5): e0267295. Doi: 10.1371/journal.pone.0267295.
[16]. Hachim A, Gu H, Kavian O, Mori M, Kwan MYW, et al. SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nat Commun. 2022; 13: 2951. doi: 10.1038/s41467-022-30699.
[17]. Chakraborty AK. Dynamics of SARS-CoV-2 ORF7a Gene Deletions and Fate of Downstream ORF7b and ORF8 Genes Expression. SunText Rev Biotechnol. 2022; 3(1): 142. Doi: https//doi.org/10.51737/2766-5097.2022.042.
[18]. Chakraborty AK. SARS-CoV-2 ORF8 gene CAA=TAA and AAA=TAA termination codon mutations found mostly in B.1.1.7 variant was independent of popular L84S mutations. Int J Clini Med Edu Res. 2022; 1(6): 192-208.
[19]. Meng B, Kemp SA, Papa G, et al. Recurrent emergence of SARS-CoV-2 Spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 2021; 35(13): 109292. Doi: 10.1016/j.celrep.2021.109292.
[20]. Guruprasad K. Geographical Distribution of Amino Acid Mutations in human SARS-CoV-2 Orf1ab polyprotein compared to the equivalent reference proteins from China. ChemRxiv. July, 2021. Preprint. Doi: https://doi.org/10.26434/chemrxiv.12951617.v1.
[21]. Liu Z, Zheng H, Lin H, Li M, Yuan R, et al. Identification of Common Deletions in the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. J Virol. 2020; 94(17): e00790-20. doi: 10.1128/JVI.00790-20.
[22]. Ju B, Fan Q, Wang M, Liao X, Guo H, Wang H, Ge X, Liu L, Zhang Z. Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections. Nat Commun. 2022; 13(1): 7120. doi: 10.1038/s41467-022-34400-8.
[23]. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature, 2022; 608: 603-608.
[24]. Tan CW, Lim BL, Young BE, Yeoh AY, et al. Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5. Lancet Microbe. 2022; 3(12): e898. doi: 10.1016/S2666-5247(22)00220-8.
[25]. Abeywardhana S, Premathilaka M, Bandaranayake U, et al. In silico study of SARS-CoV-2 spike protein RBD and human ACE-2 affinity dynamics across variants and omicron subvariants. J Med Virol. 2023; 95(1): e28406. Doi: 10.1002/jmv.28406.
[26]. Qu, P., Evans, J.P., Faraone, J.N., Zheng, Y.-M., Carlin, C., et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, and BA.2.75.2. Cell, 2022; Doi: https://doi.org/10.1016/j.chom.2022.11.012.
[27]. Wang Q, Iketani S, Li Z, Liu L, Guo Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022 Dec 14: S0092-8674(22)01531-8. doi: 10.1016/j.cell.2022.12.018.
[28]. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi PY. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022; Dec 6. doi: 10.1038/s41591-022-02162-x.
[29]. Callaway E. Coronavirus variant XBB.1.5 rises in the United States - is it a global threat? Nature. 2023; 613(7943): 222-223. doi: 10.1038/d41586-023-00014-3.
[30]. Davis-Gardner ME, Lai L, Wali B, Samaha H, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; NEJMc2214293. doi: 10.1056/NEJMc2214293.
[31]. Scarpa F, Sanna D, Benvenuto D, Borsetti A, et al. Genetic and Structural Data on the SARS-CoV-2 Omicron BQ.1 Variant Reveal Its Low Potential for Epidemiological Expansion. Int J Mol Sci. 2022; 23(23): 15264. doi: 10.3390/ijms232315264.
[32]. Sheward DJ, Kim C, Fischbach J, Sato K, et al. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. Lancet Infect Dis. 2022; 22(11): 1538-1540. doi: 10.1016/S1473-3099(22)00663-6.
[33]. Chakraborty C, Bhattacharya M, Dhama K. Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level? Ann Med Surg (Lond). 2022; 84: 104963. doi: 10.1016/j.amsu.2022.104963.
[34]. Shaheen N., et al. Could the new BA.2.75 sub-variant lead to another COVID-19 wave in the world? - Correspondence. Int. J. Surg. 2022;105
[35]. Zappa M., Verdecchia P., Angeli F. Knowing the new Omicron BA.2.75 variant ('Centaurus'): a simulation study. Eur. J. Intern. Med. 2022; S0953.
[36]. Lin J, Anjum Huma F, Irfan A, Ali SS, Waheed Y, Mohammad A, Munir M, Khan A, Wei DQJ. Structural plasticity of omicron BA.5 and BA.2.75 for enhanced ACE-dependent entry into cells. Biomol Struct Dyn. 2022:1-12. doi: 10.1080/07391102.2022.2158944.
[37]. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020; 396: 479- 488
[38]. Anderson EJ, Rouphael NG, Widge AT, et al. (2020) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New Engl J Med. Doi: https://doi.org/10.1056/NEJMoa2028436.
[39]. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med. 2023; 388(1): 89-91. doi: 10.1056/NEJMc2214302.
[40]. Bacha, U., Barrila, J., Gabelli, S.B., Kiso, Y., et al., (2008). Development of broad-spectrum halomethyl ketone inhibitors against corona virus main protease 3CL(pro). Chem. Biol. Drug Des. 72:34–49.
[41]. Chakraborty, AK. (2020c). Multi-Alignment Comparison of Coronavirus Non-Structural Proteins Nsp13-16 with Ribosomal proteins and other DNA/RNA modifying Enzymes Suggested Their Roles in the Regulation of Host Protein Synthesis. International J Clinical Medical Informatics 3(1):7-19.
[42]. Wu C, Liu Y, Yang Y, Zhang P, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020; Doi: https://doi.org/10.1016/j.apsb.2020.02.008.